Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants
Latest Information Update: 17 Jun 2025
At a glance
- Drugs INCB 057643 (Primary)
- Indications Myelodysplastic syndromes; Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Incyte Corporation
Most Recent Events
- 11 Jun 2025 Status changed from recruiting to completed.
- 02 May 2025 Status changed from not yet recruiting to recruiting.
- 29 Apr 2025 New trial record